# Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced Dyskinesia

> **NCT00607451** · PHASE1,PHASE2 · TERMINATED · sponsor: **Neurim Pharmaceuticals Ltd.** · enrollment: 8 (actual)

## Conditions studied

- Levodopa-induced Dyskinesia

## Interventions

- **DRUG:** Neu-120

## Key facts

- **NCT ID:** NCT00607451
- **Lead sponsor:** Neurim Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-03
- **Primary completion:** 2016-08-27
- **Final completion:** 2016-08-27
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2018-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00607451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00607451, "Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced Dyskinesia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00607451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*